NASDAQ OMX

Eolus har fått endelig konsesjon på det norske prosjektet Øyfjellet

Del

Hässleholm, 2016-11-16 15:00 CET (GLOBE NEWSWIRE) --
 

Eolus har fått endelig konsesjon til å bygge ut vindkraftprosjektet på Øyfjellet i Nordland fylke. Prosjektet er det største Eolus har fått konsesjon på og er på inntil 330 megawatt.

Norges Olje- og Energidepartement har i dag endelig konsesjonen for utbygging av vindkraftprosjektet på Øyfjellet i Vefsn kommune i Nordland fylke. Dette er Eolus største landbaserte prosjekt hittil. Produksjonen er på inntil 330 megawatt (MW).

Prosjektet består av inntil 110 vindmøller med en årlig produksjon på inntil 1,4 terrawatt (TWh) når parken er fullt utbygd. Eolus mål er at prosjektet skal realiseres innenfor rammene i det svensk-norske el-sertifiseringssystemet.

Prosjektet startet som et lokalt initiativ av Øyfjellet Vindpark AS. Eolus tok over prosjektet i 2012 og har utviklet det videre. I november 2014 bevilget NVE (Norges vassdrags- og energidirektorat) konsesjon for prosjektet Øyfjellet og nå har olje- og energidepartementet bevilget den endelige konsesjonen. Dette har vært en forutsetning for å realisere prosjektet.

- Det er en veldig god nyhet att vi nå har fått stadfestet konsesjonen av olje-  og energidepartementet for prosjektet på Øyfjellet. Det er et spennende og viktig prosjekt som har sterk lokal forankring. Konsesjonen gir muligheter til å få videre mot en realisering av prosjektet. De første aktivitetene vi vil starte med nå er dyptgående analyser av vindforutsetningene, optimering av parkens utseende og tilslutningen til kraftnettet, sier administrerende direktør i Eolus Per Witalisson.

Kontaktpersoner:
Per Witalisson, administrerende direktør, tlf +46 10-199 88 02
Johan Hammarqvist, kommunikasjonssjef tlf. +46 10-199 88 10

Denne informasjonen er Eolus Vind AB forpliktet til å offentligjøre ifølge EUs markedsmisbruksdirektiv. Informasjonen ble offentliggjort den 16. november kl 15.00 CET av kommunikasjonssjef Johan Hammarqvist.
 

Kort om Eolus
Eolus Vind er en av Sveriges ledende bedrifter innen vindkraft. Eolus skaper verdier i alle ledd innen rammen for prosjektutvikling og drift av vindparker og tilbyr både lokal og internasjonale investorer attraktive og konkurransekraftige investeringsobjekter i Norden og Baltikum. Siden starten i 1990 har Eolus vært involvert i nær 500 av de ca. 3300 vindkraftverkene som idag finnes i Sverige. Eolus ejer i øyeblikket en installert effekt på 38 MW vindkraft med en årlig produksjon på ca. 89 GWh miljøvennlig elektrisitet. Totalt forvalter Eolus driftsorganisajon ca. 300 MW for kunder og oss selv.

Eolus Vind AB har ca. 5000
aksjonærer. Eolus B-aksje omsettes på Nasdaq Stockholm.

For mer informasjon om Eolus,
besøk gjerne www.eolusvind.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53Pressemelding

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc

Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42Pressemelding

NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq

Colliers International Expands in Washington, D.C.18.10.2017 14:30Pressemelding

Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct.  18, 2017  (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00Pressemelding

InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC.  Anti-fibrotic therapi

Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00Pressemelding

Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.  

World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25Pressemelding

YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom